Erratum: Bapineuzumab captures the N-terminus of the Alzheimer €s disease amyloid-beta peptide in a helical conformation (Scientific Reports (2013) 3 (1302) (DOI:10.1038/srep01302));Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Miles, Luke A ^a,b,c   Crespi, Gabriela A N ^a   Doughty, Larissa ^a   Parker, Michael W ^a,b  

^a ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; BAPINEUZUMAB; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ARTICLE; CHEMISTRY; HUMAN; HYDROGEN BOND; METABOLISM; PATHOLOGY; PROTEIN BINDING; PROTEIN SECONDARY STRUCTURE; X RAY CRYSTALLOGRAPHY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROGEN BONDING; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY;

EID: 84874330804     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01618     Document Type: Erratum

References (30)

1. Selkoe, D. J. Preventing Alzheimer's disease. Science 337, 1488-1492 (2012).
2. Barnes, D. E. & Yaffe, K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 10, 819-828 (2011).
3. Mullard, A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nat. Rev. Drug Discov. 11, 657-660 (2012).
4. Salloway, S. et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070 (2009).
5. 42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 94, 1550-1555 (1997).
6. Zago, W. et al. Neutralization of soluble, synaptotoxic amyloid-b species by antibodies is epitope specific. J. Neurosci. 32, 2696-2702 (2012).
7. Demattos, R. B. et al. A plaque-specific antibody clears existing b-amyloid plaques in Alzheimer's disease mice. Neuron 76, 3523-3530 (2012).
8. Lippok, S. et al. Direct detection of antibody concentration and affinity in human serum using microscale thermophoresis. Anal. Chem. 84, 3523-3530 (2012).
9. Zirah, S. et al. Structural changes of region 1-16 of the Alzheimer disease amyloid beta-peptide upon zinc binding and in vitro aging. J. Biol. Chem. 281, 2151-2161 (2006).
10. Roccatano, D., Colombo, G., Fioroni, M. & Mark, A. E. Mechanism by which 2, 2, 2-trifluoroethanol/water mixtures stabilize secondary-structure formation in peptides: amolecular dynamics study. Proc. Natl. Acad. Sci. USA 99, 12179-12184 (2002).
11. Seubert, P. et al. Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener. Dis. 5, 65-71 (2008).
12. Colletier, J. P. et al. Molecular basis for amyloid-beta polymorphism. Proc. Natl. Acad. Sci. USA 108, 16938-16943 (2011).
13. Stroud, J. C., Liu, C., Teng, P. K. & Eisenberg, D. Toxic fibrillar oligomers of amyloid-b have cross-b structure. Proc. Natl. Acad. Sci. USA 109, 7717-7722 (2012).
14. Sergeant, N. et al. Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J. Neurochem. 85, 1581-1591 (2003).
15. Nussbaum, J. M. et al. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-b. Nature 485, 651-655 (2012).
16. Gardberg, A. S. et al. Molecular basis for passive immunotherapy of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 104, 15659-15664 (2007).
17. Miles, L. A. et al. Amyloid-beta-anti-amyloid-beta complex structure reveals an extended conformation in the immunodominant B-cell epitope. J. Mol. Biol. 377, 181-192 (2008).
18. Wun, K. S. et al. Crystallization and preliminary X-ray diffraction analysis of the Fab fragment of WO2, anantibody specific for the Abeta peptides associated with Alzheimer's disease. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 64, 438-441 (2008).
19. Basi, G. S. et al. Structural correlates of antibodies associated with acute reversal of Amyloid b-related behavioral deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 285, 3417-3427 (2010).
20. Bohrmann, B. et al. Gantenerumab: a novel human anti-Ab antibody demonstrates sustained cerebral amyloid-b binding and elicits cell-mediated removal of human amyloid-b. J. Alzheimers Dis. 28, 49-69 (2012).
21. Callaway, E. Alzheimer's drugs take a new tack. Nature 489, 13-14 (2012).
22. Zahnd, C., Spinelli, S., Luginbühl, B., Amstutz, P., Cambillau, C. & Plückthun, A. Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity. J. Biol. Chem. 279, 18870-18877 (2004).
23. Schroeter, S. & Games, K. D. Prevention and treatment of cerebral amyloid angiopathy. US Patent Application 20080292625 (2008).
24. Obmolova, G., Malia, T. J., Teplyakov, A., Sweet, R. & Gilliland, G. L. Promoting crystallization of antibody-antigen complexes via microseed matrix screening. Acta Crystallogr. D Biol. Crystallogr. 66, 927-933 (2010).
25. McPhillips, T. M. et al. Blu-Ice and the Distributed Control System: software for data acquisition and instrument control at macromolecular crystallography beamlines. J. Synchrotron Radiat. 9, 401-406 (2002).
26. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in the oscillation mode. Methods Enzymol. 276, 307-326 (1997).
27. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
28. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
29. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010).
30. Laskowski, R. A. & Swindells, M. B. J. LigPlot1: multiple ligand-protein interaction diagrams for drug discovery. Chem. Inf. Model. 51, 2778-2786 (2011).